PMID- 25115686
OWN - NLM
STAT- MEDLINE
DCOM- 20150304
LR  - 20211021
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 12
DP  - 2014 Aug 14
TI  - A pilot clinical study of resveratrol in postmenopausal women with high body mass 
      index: effects on systemic sex steroid hormones.
PG  - 223
LID - 10.1186/s12967-014-0223-0 [doi]
LID - 223
AB  - BACKGROUND: Breast cancer risk is partially determined by several hormone-related 
      factors. Preclinical and clinical studies suggested that resveratrol may modulate 
      these hormonal factors. METHODS: We conducted a pilot study in postmenopausal 
      women with high body mass index (BMI >/= 25 kg/m2) to determine the clinical effect 
      of resveratrol on systemic sex steroid hormones. Forty subjects initiated the 
      resveratrol intervention (1 gm daily for 12 weeks) with six withdrawn early due 
      to adverse events (AEs). Thirty-four subjects completed the intervention. 
      RESULTS: Resveratrol intervention did not result in significant changes in serum 
      concentrations of estradiol, estrone, and testosterone but led to an average of 
      10% increase in the concentrations of sex steroid hormone binding globulin 
      (SHBG). Resveratrol intervention resulted in an average of 73% increase in 
      urinary 2-hydroxyestrone (2-OHE1) levels leading to a favorable change in urinary 
      2-OHE1/16alpha-OHE1 ratio. One participant had asymptomatic Grade 4 elevation of 
      liver enzymes at the end of study intervention. Two subjects had Grade 3 skin 
      rashes. The remaining adverse events were Grade 1 or 2 events. The most common 
      adverse events were diarrhea and increased total cholesterol, reported in 30% and 
      27.5% of the subjects, respectively. CONCLUSION: We conclude that among 
      overweight and obese postmenopausal women, daily 1 gm dose of resveratrol has 
      favorable effects on estrogen metabolism and SHBG. Further placebo-controlled 
      studies are needed to confirm our findings on these hormone-related breast cancer 
      risk factors and the attribution of the adverse effects observed in the study 
      population. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01370889.
FAU - Chow, H-H Sherry
AU  - Chow HH
AD  - University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, 85724, AZ, USA. 
      schow@azcc.arizona.edu.
FAU - Garland, Linda L
AU  - Garland LL
FAU - Heckman-Stoddard, Brandy M
AU  - Heckman-Stoddard BM
FAU - Hsu, Chiu-Hsieh
AU  - Hsu CH
FAU - Butler, Valerie D
AU  - Butler VD
FAU - Cordova, Catherine A
AU  - Cordova CA
FAU - Chew, Wade M
AU  - Chew WM
FAU - Cornelison, Terri L
AU  - Cornelison TL
LA  - eng
SI  - ClinicalTrials.gov/NCT01370889
GR  - N01CN35158/CA/NCI NIH HHS/United States
GR  - P30 CA023074/CA/NCI NIH HHS/United States
GR  - CA023074/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140814
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Estrogens)
RN  - 0 (Gonadal Steroid Hormones)
RN  - 0 (Stilbenes)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Adult
MH  - *Body Mass Index
MH  - Demography
MH  - Estrogens/blood
MH  - Female
MH  - Gonadal Steroid Hormones/*blood
MH  - Humans
MH  - Middle Aged
MH  - Pilot Projects
MH  - Postmenopause/blood/*drug effects
MH  - Resveratrol
MH  - Stilbenes/adverse effects/blood/*pharmacology
PMC - PMC4243716
EDAT- 2014/08/15 06:00
MHDA- 2015/03/05 06:00
PMCR- 2014/08/14
CRDT- 2014/08/14 06:00
PHST- 2014/04/17 00:00 [received]
PHST- 2014/08/01 00:00 [accepted]
PHST- 2014/08/14 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2015/03/05 06:00 [medline]
PHST- 2014/08/14 00:00 [pmc-release]
AID - s12967-014-0223-0 [pii]
AID - 223 [pii]
AID - 10.1186/s12967-014-0223-0 [doi]
PST - epublish
SO  - J Transl Med. 2014 Aug 14;12:223. doi: 10.1186/s12967-014-0223-0.